Pfizer's Litfulo Succeeds in Late-Stage Vitiligo Clinical Trials

Key Facts

In a move that strengthens the company's position in the immunology sector, Pfizer announced positive results for its oral drug Litfulo in treating nonsegmental vitiligo. According to reports, the drug met the primary endpoints of two Phase 3 clinical trials, showing significant success in restoring skin pigmentation. The treatment works by blocking specific proteins within immune cells, preventing the immune system from attacking pigment-producing cells.

These results support the company's therapeutic portfolio as Pfizer plans to submit the data to global regulators for approval in treating vitiligo in adults. Per market data, PFE stock closed at $25.25 on July 28, 2026, with a daily range between $24.94 and $25.50. The success of these trials, which enrolled 2,174 patients, represents the largest late-stage program evaluating an oral treatment for this condition.

Investors are now watching the timeline for regulatory submissions as a future catalyst for revenue growth, with PFE shares at $25.25 (close July 28, 2026). Looking at the economic calendar, while no direct pharma-sector events are scheduled, markets await the U.S. Durable Goods Orders on July 27 as a broader sentiment driver.